Analyst: Unexpected Novo upgrade "demonstrates positive development"

Novo Nordisk's Friday upgrade to its financial guidance surprised analysts at Sydbank, who see it as an expression of strong growth momentum for the company's GLP and obesity business.

Photo: Novo Nordisk / PR

After a quarter of taking market shares with diabetes drug Ozempic and increased sales of GLP-1 analog and obesity treatments, Novo Nordisk upgraded its full-year financial guidance on Friday.

Senior Analyst at Sydbank Søren Løntoft Hansen tells Marketwire that this demonstrates positive development.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs